Japanese researchers at the University of Tokyo have pioneered a groundbreaking oral cholera vaccine, MucoRice-CTB, cultivated in genetically modified rice—no injections required.
The appeal of an oral vaccine is clear: sip a liquid instead of enduring a needle. In a June 26, 2021, press release, University of Tokyo experts detailed MucoRice-CTB, derived from GMO rice. Cholera, caused by Vibrio cholerae and first identified in 1854, still claims around 100,000 lives annually amid nearly 4 million cases.
Four existing oral cholera vaccines, delivered as tongue drops from attenuated dead Vibrio cholerae strains, demand refrigeration and can trigger side effects like nausea, fatigue, or abdominal pain. In contrast, MucoRice-CTB remains stable at room temperature as a simple powder mixed with water for effortless use.
This vaccine is produced in genetically modified short-grain rice, yielding a non-toxic B subunit (CTB) from the seeds. The immune system targets CTB accumulated in membrane-bound protein bodies—natural capsules shielding the antigen from digestive enzymes. Cultivation occurs indoors via hydroponics to prevent environmental contamination.
No cholera vaccine offers 100% efficacy, and MucoRice-CTB follows suit. As lead researcher Hiroshi Kiyono explains, it leverages the gut's immune system for robust antibody production. Oral exposure generates specific IgG and IgA antibodies, unlike injected vaccines that produce only IgG.
In trials with 30 volunteers, most developed IgG and IgA two to four months post-ingestion. Yet, 11 showed weak or no response, likely due to individual gut microbiota variations. A diverse microbiome correlates with stronger immune responses—a common challenge in oral vaccine development.
